- Home
- COYA vs GNLX Comparison
COYA vs GNLX Comparison
Compare COYA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | GNLX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.7M | 110.4M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | COYA | GNLX |
|---|---|---|
| Price | $5.00 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.80 | ★ $17.25 |
| AVG Volume (30 Days) | 133.4K | ★ 228.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $763.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $2.29 |
| 52 Week High | $7.75 | $8.54 |
Technical Indicators
Market Signals| Indicator | COYA | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 42.41 |
| Support Level | $4.42 | $2.34 |
| Resistance Level | $5.17 | $2.86 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 62.75 | 28.57 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.